데이터가 없습니다.

1. Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer [ SCIENTIFIC REPORTS ] - 2023.11.16
2. Randomized phase II study of capecitabine plus cisplatin with or without sorafenib in patients with metastatic gastric cancer (STARGATE) [ Cancer Medicine ] - 2023.04.01
3. Predictive biomarkers for the efficacy of nivolumab as >= 3(rd)-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial [ BMC CANCER ] - 2022.04.09
4. Prognostic value of natural killer cell activity for patients with HER2+advanced gastric cancer treated with first-line fluoropyrimidine-platinum doublet plus trastuzumab [ CANCER IMMUNOLOGY IMMUNOTHERAPY ] - 2022.04.01
5. Insertion-deletion rate is a qualitative aspect of the tumor mutation burden associated with the clinical outcomes of gastric cancer patients treated with nivolumab [ GASTRIC CANCER ] - 2022.01.01
6. Trends in Chemotherapy Patterns and Survival of Patients with Advanced Gastric Cancer over a 16-Year Period: Impact of Anti-HER2-Targeted Agent in the Real-World Setting [ CANCER RESEARCH AND TREATMENT ] - 2021.04.01
7. Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial) [ GASTRIC CANCER ] - 2021.01.01
8. Clinical implications of neutrophil-to-lymphocyte ratio and MDSC kinetics in gastric cancer patients treated with ramucirumab plus paclitaxel [ CHINESE JOURNAL OF CANCER RESEARCH ] - 2020.10.31
9. Establishment of patient-derived xenografts from patients with gastrointestinal stromal tumors: analysis of clinicopathological characteristics related to engraftment success [ SCIENTIFIC REPORTS ] - 2020.05.14
10. Role of Resection Following Focal Progression with Standard Doses of Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors: Results of Propensity Score Analyses [ ONCOLOGIST ] - 2019.12.01
11. Association between the exposure to anti-angiogenic agents and tumour immune microenvironment in advanced gastrointestinal stromal tumours [ BRITISH JOURNAL OF CANCER ] - 2019.11.01
12. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatiniband Sunitinib [ ONCOLOGIST ] - 2019.11.01
13. Clinical significance of MET gene amplification in metastatic or locally advanced gastric cancer treated with first-line fluoropyrimidine and platinum combination chemotherapy [ CHINESE JOURNAL OF CANCER RESEARCH ] - 2019.08.01
14. Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience [ CANCER MEDICINE ] - 2019.03.01
15. Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11 [ GASTRIC CANCER ] - 2018.09.01
16. Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG) [ GASTRIC CANCER ] - 2018.09.01
17. Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis [ CANCER RESEARCH AND TREATMENT ] - 2018.04.01
18. Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis [ GASTRIC CANCER ] - 2017.11.01
19. Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors [ ONCOTARGET ] - 2017.09.11
20. Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers [ ONCOTARGET ] - 2017.05.16
21. A Phase I/IIa Study of DHP107, a Novel Oral Paclitaxel Formulation, in Patients with Advanced Solid Tumors or Gastric Cancer [ ONCOLOGIST ] - 2017.02.01
22. Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor [ CANCER RESEARCH AND TREATMENT ] - 2016.10.01
23. Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer [ GASTRIC CANCER ] - 2016.04.01
24. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1) [ EUROPEAN JOURNAL OF CANCER ] - 2016.01.01
25. Risk Factors for Selection of Patients at High Risk of Recurrenceor Death after Complete Surgical Resection in Stage I Gastric Cancer [ Gastric Cancer ] - 2016.01.01
26. Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS). [ ANNALS OF ONCOLOGY ] - 2015.10.01
27. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. [ EUROPEAN JOURNAL OF CANCER ] - 2015.03.01
28. Analysis of serum protein biomarkers, circulating tumor DNA, and dovitinib activity in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumors. [ ANNALS OF ONCOLOGY ] - 2014.11.25
29. Significant Symptom Relief with Hepatic Artery Embolization. [ 대한내과학회지 ] - 2014.09.01
30. A Case of Complete Remission of Mucosa-associated Lymphoid Tissue Lymphoma of the Urinary Bladder after Eradication of Helicobacter Pylori [ 대한내과학회지 ] - 2014.08.01
31. Neoadjuvant chemotherapy in localized resectable stomach cancer [ KOREAN JOURNAL OF CLINICAL ONCOLOGY ] - 2014.06.30
32. A phase II study of neoadjuvant docetaxel, oxaliplatin, and S 1 (DOS) chemotherapy followed by surgery and adjuvant S 1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma [ CANCER CHEMOTHERAPY AND PHARMACOLOGY ] - 2013.10.01
33. Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group [ INVESTIGATIONAL NEW DRUGS ] - 2012.12.01
34. Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer. [ CANCER CHEMOTHERAPY AND PHARMACOLOGY ] - 2012.10.01
35. 위암의 보조항암화학요법 [ 대한내과학회 ] - 2012.09.01
36. Changes in Imatinib Plasma Trough Level during Long-term Treatment of Patients with Advanced Gastrointestinal Stromal Tumors: Correlation between Changes in Covariates and Imatinib Exposure [ INVESTIGATIONAL NEW DRUGS ] - 2012.08.01
37. Three week combination chemotherapy with S-1 and cisplatin as first-line treatment in patients with advanced gastric cancer [ GASTRIC CANCER ] - 2012.07.01
38. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study [ ACTA ONCOLOGICA ] - 2012.04.01
39. Sunitinib as a second-line therapy for advanced GISTs after failure of imatinib: relationship between efficacy and tumor genotype in Korean patients. [ INVESTIGATIONAL NEW DRUGS ] - 2012.04.01
40. Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum [ BRITISH JOURNAL OF CANCER ] - 2012.03.13
41. Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. [ CANCER CHEMOTHERAPY AND PHARMACOLOGY ] - 2011.08.01
42. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer [ CANCER CHEMOTHERAPY AND PHARMACOLOGY ] - 2010.07.12
43. ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer [ EXPERT REVIEW OF ANTICANCER THERAPY ] - 2009.12.09
44. A Prospective, Multicenter, Phase 2 Study of Imatinib Mesylate in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor [ ONCOLOGY ] - 2009.03.23
45. Dose Escalation of Imatinib After Failure of Standard Dose in Korean Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumor [ JAPANESE JOURNAL OF CLINICAL ONCOLOGY ] - 2009.02.03
46. Primary Central Mervous System Margical Zone B-Cell Lymphoma of the Basal Ganglia Mimicking Low-Grade Glioma: A Case Report and Review of the Literature. [ CLINICAL LYMPHOMA & MYELOMA ] - 2008.07.08
47. Prognostic significance of p53 gene mutations and protein overexpression in localized gastrointestinal stromal tumours [ HISTOPATHOLOGY ] - 2007.02.20
48. Patterns of Progression in Gastrointestinal Stromal Tumor Treated with Imatinib Mesylate. [ JAPANESE JOURNAL OF CLINICAL ONCOLOGY ] - 2006.01.17
49. Subclassification of diffuse large B-cell lymphomas according to the REAL classification: Distinction of immunoblastic and non-immunoblastic subtypes [ 대한내과학회 ] - 2003.05.01

1. 간암의 합성치사 네트워크 검증(3) - 2017.03.01 ~ 2018.02.28
2. 근치적으로 절제한 IB기 (AJCC 제 6판 기준) 위암을 대상으로 하는 수술 후 보조요법 Capecitabine vs 관찰 단독의 제 III상 임상시험 - 2015.05.01 ~ 2016.04.30
3. 백금과 플루오로피리미딘의 1차 선택 요법 후에 진행된 진행성 위선암 또는 위식도접합부 선암 환자를 대상으로 펨브롤리주맙 (MK-3475)을 파클리탁셀과 비교하여 평가하기 위한 제III상, 무작위배정, 공개라벨, 임상시험 - 2015.04.13 ~ 2017.03.31
4. 위암 복수 및 조기발생 위암의 생분자 시그너처 발굴 - 2014.06.01 ~ 2015.05.31
5. 근치적으로 절제한 IB기 (AJCC 제 6판 기준) 위암을 대상으로 하는 수술 후 보조요법 Capecitabine vs 관찰 단독의 제 III상 임상시험 - 2014.05.01 ~ 2015.04.30
6. 진행성 또는 재발성 위 및 위식도 접합부 암 피험자를 대상으로 이차 치료로서 니모투주맙과 이리노테칸 병용요법 대비 이리노테칸 단일요법의 유효성을 비교하기 위한 무작위배정, 공개, 일본-한국 공동 제 3 상 임상시험 - 2013.06.24 ~ 2018.12.31
7. 위암 복수 및 조기발생 위암의 생분자 시그너처의 발굴 - 2013.06.01 ~ 2014.05.31
8. 위암 복수/흉수 및 조기발생 위암의 생분자 시그너처의 발굴 - 2012.08.01 ~ 2013.07.31
9. 진행성 위암환자에서 1차 치료제로서 S-1과 Cisplatin 병용요법(3주요법) 대 S-1과 Oxaliplatin 병용요법의 다기관 무작위배정, 개방라벨 제3상 임상연구 - 2012.05.07 ~ 2015.12.31
10. GIST(위장관기저종양)에서 수술 후 Imatinib의 효과 - 2008.07.01 ~ 2011.12.31

데이터가 없습니다.

      데이터가 없습니다.

 공지